Trial Profile

Multicenter Randomized Controlled Trial of Combination Antiemetic Therapy With Aprepitant / Fosaprepitant in Patients With Colorectal Cancer Receiving Oxaliplatin-based Chemotherapy

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 01 Mar 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aprepitant (Primary) ; Fosaprepitant (Primary) ; Dexamethasone; Dexamethasone; Serotonin 3 receptor antagonists
Indications Chemotherapy-induced nausea and vomiting
Focus Therapeutic Use
Acronyms SENRI

01 Feb 2021 Results of pooled analysis from SENRI and other two studies assessing whether treatment with the triplet antiemetic prophylaxis involving aprepitant, is more effective in controlling delayed CINV than prophylaxis with palonosetron and dexamethasone, published in the Cancer Science
21 Jan 2017 Results of subgroup analysis of SENRI trial (n=370) presented at the 2017 Gastrointestinal Cancers Symposium
04 Jul 2015 Results presented at the 17th World Congress on Gastrointestinal Cancer.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com